Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Microenvironmental stresses induce HLA-E/Qa-1 surface expression and thereby reduce CD8(+) T-cell recognition of stressed cells.
Sasaki T, Kanaseki T, Shionoya Y, Tokita S, Miyamoto S, Saka E, Kochin V, Takasawa A, Hirohashi Y, Tamura Y, Miyazaki A, Torigoe T, Hiratsuka H, Sato N. Sasaki T, et al. Among authors: tokita s. Eur J Immunol. 2016 Apr;46(4):929-40. doi: 10.1002/eji.201545835. Epub 2016 Feb 10. Eur J Immunol. 2016. PMID: 26711740 Free article.
The Antigen ASB4 on Cancer Stem Cells Serves as a Target for CTL Immunotherapy of Colorectal Cancer.
Miyamoto S, Kochin V, Kanaseki T, Hongo A, Tokita S, Kikuchi Y, Takaya A, Hirohashi Y, Tsukahara T, Terui T, Ishitani K, Hata F, Takemasa I, Miyazaki A, Hiratsuka H, Sato N, Torigoe T. Miyamoto S, et al. Among authors: tokita s. Cancer Immunol Res. 2018 Mar;6(3):358-369. doi: 10.1158/2326-6066.CIR-17-0518. Epub 2018 Jan 25. Cancer Immunol Res. 2018. PMID: 29371260
HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses.
Kochin V, Kanaseki T, Tokita S, Miyamoto S, Shionoya Y, Kikuchi Y, Morooka D, Hirohashi Y, Tsukahara T, Watanabe K, Toji S, Kokai Y, Sato N, Torigoe T. Kochin V, et al. Among authors: tokita s. Oncoimmunology. 2017 Feb 16;6(4):e1293214. doi: 10.1080/2162402X.2017.1293214. eCollection 2017. Oncoimmunology. 2017. PMID: 28533942 Free PMC article.
GRIK2 is a target for bladder cancer stem-like cell-targeting immunotherapy.
Miyata H, Hirohashi Y, Yamada S, Yanagawa J, Murai A, Hashimoto S, Tokita S, Hori K, Abe T, Kubo T, Tsukahara T, Kanaseki T, Shinohara N, Torigoe T. Miyata H, et al. Among authors: tokita s. Cancer Immunol Immunother. 2022 Apr;71(4):795-806. doi: 10.1007/s00262-021-03025-z. Epub 2021 Aug 18. Cancer Immunol Immunother. 2022. PMID: 34405274 Free PMC article.
192 results